Probenecid, Pannexin 1 Channels for Alcohol Use Disorder

What this Trial Is About

Researchers are evaluating the effects of the drug probenecid on alcohol craving and consumption in adults with Alcohol Use Disorder (AUD). This Phase 2, double-blind, randomized controlled trial aims to test whether taking 2 grams of probenecid daily can reduce both acute and naturalistic alcohol craving, as well as actual alcohol consumption. The study is sponsored by Brown University and focuses on individuals with moderate to severe AUD as defined by DSM-5 criteria. The study compares two groups: one receiving oral probenecid tablets (2 grams daily) and the other receiving inactive placebo tablets. The trial lasts 16 weeks and includes a laboratory phase to measure acute craving and a naturalistic phase to monitor craving and drinking in real-world settings. Participants will be randomly assigned to either the probenecid or placebo group, and both participants and researchers are blinded to which treatment is given. Participants will visit the study site regularly for assessments including breath alcohol content tests, questionnaires, medical exams, and lab tests. The primary outcome is the level of acute alcohol craving over 5 weeks, with a secondary outcome measuring craving over 12 weeks. The study monitors health status and adherence to procedures throughout. Total participation spans the 16-week trial period and includes safety checks and outcome evaluations.

Probenecid Administration for Alcohol Craving and Consumption